FDA Workshop External Defibrillator Improvement Initiative December 15-16, 2010 MDR Reporting Factors Over the Past 5 Years Derek Smith Senior Vice President.

Slides:



Advertisements
Similar presentations
Mary Ellen Turner MD, MPH Vice-President
Advertisements

Stress in Nurses Starting Work Andy Smith. Healthy Minds at Work: An ESF funded project.
Take Two Software Updates and See Me in the Morning: The Case for Software Security Evaluations of Medical Devices Steve Hanna 1, Rolf Rolles 4, Andres.
Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010
2014 Annual Meeting of Stockholders Dan Moore, President & Chief Executive Officer September 18, 2014.
Health Coaching for Behaviour Change
Capturing and Reporting Adverse Events in Clinical Research
Recent Changes to HDR Policy and Procedures Felicity Roddick Associate Dean Research and Innovation.
LAQM.PG(S)(09) – new biomass guidance. PG(S)(09) published in February Reflects changes since PG(S)(03) 2003: - biomass burning not a significant issue.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
EU Vigilance New Manufacturer Incident Report Form Piloting arrangements.
How Safe Are We? Frank Federico. Safety and Quality Safety as a dimension of quality IOM STEEP – Safe – Timely – Effective – Efficient – Patient-centered.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
Los Angeles Transportation Club May 14, 2013 Scott Satterlee C.H. Robinson Senior Vice President.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
MassMEDIC Risk Management: Legal and Liability Issues with Home Healthcare Products Raymond C. Zemlin Goodwin Procter LLP (March 9, 2006) ©2006. Goodwin.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
Occurrence Reports. An occurrence report is a document used to record an event when it occurs Occurrences are reported each time an occurrence occurs.
Hype Cycle
Investigational Devices and Humanitarian Use Devices June 2007.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
Evaluation of Psychosocial Support Services for Adolescent and Young Adult Patients at Roswell Park Cancer Institute Allison Polakiewicz, MPA Project Proposal.
Community surgery : staying out of trouble. Miss Nicola Lennard : 12 June 2015:
MarketsandMarkets Presents Cardiac Monitoring Market worth $23.3 Billion – 2017
Internal market, Industry, Entrepreneurship and SMEs Commission report to EP and Council on the operation of the system of access to vehicle repair and.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
COMPLAINT HANDLING PROCESS. DEFINITION OF A COMPLAINT Any written, electronic, or oral communication that alleges deficiencies of a distributed device.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
IRB Presentation to the Pediatric Ethics Subcommittee of the FDA regarding “Gonadotropin Releasing Hormone (GnRH) Agonist Test in Disorders of Puberty”
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
© Copyright 2005 Frost & Sullivan. All Rights Reserved. U.S. Compression Therapy Market Low Awareness among End Users a Key Challenge for Compression Market.
Korea Responsible Care Council RESPONSIBLE CARE ® in KOREA March 2001 By KOREA RESPONSIBLE CARE COUNCIL.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
MEM Cybersecurity Working Group Update to PCD Technical Committee
Regulation of Medical Devices: Importance of a Globally Harmonized Approach Nicole Taylor Smith, JD September 2017.
Objectives & Standards
MEM Cybersecurity Working Group Update to PCD Technical Committee
Developing the Overall Audit Plan and Audit Program
Published on – 1 August, 2016 | Number of pages : 150
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Focusing on Quality at UTT
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
9. Introduction to signal detection
Combination products The paradigm shift
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Women’s Health Technologies CRN
NHS Blackburn with Darwen Clinical Commissioning Group
ICPHSO 13 November 2018 Regulator Panel Yasuko Iwai, Chair
Tobey Clark, Director*, Burlington USA
HeartSafe Community A Proposal to Make Your City the Best Place in the World to be if you have a Sudden Cardiac Arrest.
Market Industry Reports. Infusion Pump Market by Product, End User, and Regional Forecasts to 2030 Market Industry Reports.
AFA - TEA DIRECTORATE IMPLEMENTATION OF VOLUNTARY SUSTAINABILITY CERTIFICATION (VSC) IN THE KENYA TEA INDUSTRY: STATUS AND CHALLENGES by WILLY K MUTAI.
Global Defibrillators Market (By Product Types, End Users, Regions), Key Company Profiles - Forecast to 2025
Presentation transcript:

FDA Workshop External Defibrillator Improvement Initiative December 15-16, 2010 MDR Reporting Factors Over the Past 5 Years Derek Smith Senior Vice President General Manager Therapeutic Care Philips Healthcare

Global Automated External Defibrillators (AED) Market: Demand to Drive Growth; June 2009 U.S., European and Japanese External Defibrillation (PAD) Market Report. Frost & Sullivan Valenzuela TD, et al. N Engl J Med. 2000;343: Caffrey S, et al. N Engl J Med. 2002;347: AED Milestones The Population of AEDs Has Increased Significantly Over the Past 5 Years AED Milestones AEDs Worldwide

Reporting Regulation (21CFR 803) for External Defibrillators “… An event that manufacturers or importers become aware of that reasonably suggests that one of their marketed devices: –May have caused or contributed to a death or serious injury, or –Has malfunctioned and that the device or a similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.” 3

Challenges for External Defibrillator Reporting In many types of emergencies where an external defibrillator is used, the patient is already severely ill and the likelihood of survival is low. Defibrillation therapy can be highly effective, but only with certain patients suffering from specific conditions. When Philips investigates events where a patient did not survive, it is often difficult to obtain the information needed to assess whether the patient could have benefited from defibrillation therapy, Because the reporting standard is “may have caused or contributed to death or serious injury, whether an event is reported depends more on how much information we were able collect, rather than on the actual contribution of the defibrillator to the patient outcome. 4 MDR Guidance Document. September 9, 1994.

Challenges for External Defibrillator Reporting If the defibrillator issues an alert that it may need services while sitting on a crash cart, in a wall cabinet or in a closet long before it is needed in emergency,, the conservative approach under the regulations is still to submit an MDR. However, should a report be made “in cases where the manufacturer has data showing the issue can be detected prior to emergency use?” Knowing exactly what to report and what not to report in these situations has led Philips to adopt a conservative interpretation of “may have caused or contributed to death or serious injury” resulting in an aggressive approach to MDR reporting over the past 5 years 4 MDR Guidance Document. September 9, 1994.

Philips Experience with MDR Reporting The number of MDRs from Philips has increased over the past 5 years Aggressive reporting and an increased number of units in the field have been significant factors Philips experience is consistent with published literature on MDRs and lives saved 5 Shah JS, Maisel WH. Recalls and Safety Alerts Affecting Automated External Defibrillators. JAMA. 2006; 296:

Our Mission is to Help Improve and Save Lives External defibrillators are doing this 6

Recommendations for Moving Forward Collaborate with clinicians, the FDA, and industry to fully understand how we can further improve outcomes –“We are never satisfied” Meeting of FDA/manufacturers to update 1994 MDR guidance document that reflects the modern use of external defibrillators so that reporting better reflects field performance and offers better data for dialogue on future generation defibrillator development 7